DNA variations of serotonin transporter gene can influence drinking intensity
Do the biological underpinnings of heart failure share more in common with cancerous tumors than other cardiovascular diseases? Research presented at American Heart Association meeting may show why heart failure treatments fail. A team of Medical University of South Carolina (MUSC) researchers and cardiologists are presenting a number of studies at the American Heart Association
Full Post: Research shows why some heart failure treatments fail
The brain’s serotonergic system plays an important role in alcohol preference and consumption.
New findings show that specific DNA sequence variations of the serotonin transporter gene can influence drinking intensity among alcohol-dependent individuals.
The brain’s serotonergic system plays an important role in alcohol preference and consumption. The serotonin transporter gene (SLC6A4), in particular, may regulate a person’s propensity for severe drinking. A study of six different single nucleotide polymorphisms - DNA sequence variations - of SLC6A4 has found that they influence drinking intensity among alcohol-dependent (AD) individuals in treatment.
Results will be published in the February 2009 issue of Alcoholism: Clinical & Experimental Research and are currently available at Early View.
“Serotonin is a neurochemical that carries information between nerve cells in the brain, mediating the rewarding effects of alcohol,” explained Ming D. Li, Jean and Ronald Butcher Professor at the University of Virginia and corresponding author for the study. “Acute drinking increases serotonin release and signaling in brain regions involved in controlling consumption of alcohol, while chronic drinking reduces serotonergic function, leading to a serotonin-deficient state. One hypothesis is that alcoholics drink to alleviate this serotonin-deficient state.”
Given that the serotonin transporter is a well-known pharmacological target, added Robert A. Philibert, professor of psychiatry and director of the Laboratory of Psychiatric Genetics at the University of Iowa, researchers are using relatively larger study samples and more in-depth measurements and analyses to try to develop more personalized approaches to alcohol treatment.
“An implicit assumption of the Human Genome Project was that deciphering of the human genome would lead to better treatment,” said Philibert. “By and large, that promise has not yet been realized,-particularly for those with psychiatric illnesses.”
Li agreed. “Alcoholics are a heterogeneous group in terms of their drinking patterns, etiology of the disorder, and social background,” he said. “All these factors may affect treatment outcomes, as well as the development of other general medical complications because of heavy drinking. One of the main goals of treatment is to reduce the intensity of drinking. Therefore, finding a functional genetic marker could be used for sub-typing alcoholics and better determining which treatment methods can target specific underlying molecular mechanisms.”
Li and his colleagues analyzed associations between drinking intensity among 275 (216 males, 59 females) AD individuals seeking treatment and six SLC6A4 polymorphisms. Of the six polymorphisms examined, rs1042173 in the 3′ untranslated region of SLC6A4 showed a significant association with drinking intensity. The G allele carriers for rs1042173 were associated with significantly lower drinking intensity compared to T allele homozygotes.
“In other words,” said Li, “we detected a genetic variant caused by a single-nucleotide difference in the DNA sequence of serotonin transporter gene that could predict drinking intensity in alcoholics. In this population of heavy drinking adult alcoholics of European descent, those who carried two alleles of T drank more intensely than those who carried one or two alleles of G.”
The researchers also investigated the possible mechanisms by which these two alleles contributed to the change in drinking behavior.
“Given the location of the genetic variation within the gene, we hypothesized that T and G alleles may have differences in serotonin transporter expression levels affecting the function of serotonergic system,” said Li. “We transfected cells with plasmid carrying either T or G alleles of the gene, and measured the levels of serotonin transporter mRNA and proteins in these transfected cells. We found that cells carrying T allele, the variant associated with more intense drinking, had lower serotonin transporter expression levels than cells carrying G allele.”
All in all, said Philibert, this paper establishes linkages between a genetic marker and quantitative clinical measures. “It further connects the laboratory benchtop with the patient,” he said.
“Some individuals may possess inherent risk factors for more intense drinking than others,” said Li, “making them more vulnerable to complications arising from heavy drinking. In future studies, we hope to investigate whether this genetic variant can be used as a marker to predict treatment outcomes of different serotonergic agents.”
Abnormalities in genes that repair mistakes in DNA replication may help identify people who are at high risk of developing pancreatic cancer, a research team from The University of Texas M. D. Anderson Cancer Center reports in the Jan. 15 issue of Clinical Cancer Research. Defects in these critical DNA repair genes may act alone
Full Post: Defects in critical DNA repair genes may predict pancreatic cancer risk
It is a well-known fact in drug trials that individuals can respond just as well to placebos, sugar pills, as to the active drug. On the other hand, it is difficult to explain why only certain people get better from placebos. A team of researchers from Uppsala University and Gothenburg University have now found gene
Full Post: Discovery of gene variants that impact the placebo effect
An enzyme that is overexpressed in pancreatic cancer cells may hold the key to successfully treating the disease with targeted immunotherapy, researchers from Thomas Jefferson University reported at the 2008 Annual Meeting of the Southern Surgical Association. Previous data show that a protein, indoleamine 2,3-dioxygenase (IDO), is overexpressed in pancreatic ductal adenocarcinomas, according to Jonathan
Full Post: Protein indoleamine 2,3-dioxygenase points to new pancreatic cancer therapies
Chronic drinking is a risk factor for colorectal cancer, possibly through the effects of acetaldehyde, which is created by the alcohol dehydrogenase (ADH) enzyme. This study investigated if a polymorphism of the ADH1C gene that is found in Caucasians may effect acetaldehyde concentrations. Findings confirm ADH1C*1 as a genetic risk marker for colorectal tumors among
Full Post: Drinkers with the ADH1C gene at greater risk of colorectal cancer
A Newcastle University study involving thousands of families is helping prospective parents work out whether they are likely to have sons or daughters. The work by Corry Gellatly, a research scientist at the university, has shown that men inherit a tendency to have more sons or more daughters from their parents. This means that a
Full Post: Men inherit tendency to have more sons or more daughters from their parents